Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
RSV Inhibitor
AZ-27 is a selective inhibitor of respiratory syncytial virus (RSV) by targeting its polymerase activity. This compound exhibits the ability to differentially suppress various RSV polymerase functions at the promoter level, effectively inhibiting the early stages of mRNA transcription and genome replication. AZ-27 is suitable for research applications focused on understanding RSV pathogenesis and developing antiviral strategies. -
RSV L protein Inhibitor
AZD4316 is an inhibitor of the respiratory syncytial virus (RSV) L protein, demonstrating significant antiviral activity against RSV A subtypes, including strain A2. This compound effectively hinders viral replication during the early stages of infection, particularly at the viral entry phase. However, its efficacy diminishes when administered 12-24 hours post-infection. AZD4316 is valuable for research focused on RSV infection mechanisms and potential therapeutic strategies. -
RSV Inhibitor
RSV-IN-13 is a selective inhibitor of respiratory syncytial virus (RSV) fusion protein, exhibiting antiviral activity. It demonstrates an EC50 of 444.2 nM against the RSV A2 strain, with a CC90 of 23.7 μM in HepG2 cells. By effectively blocking the entry of the virus into host cells, RSV-IN-13 serves as a valuable tool for research on RSV infection and pathogenesis. -
RSV Inhibitor
A 33903 is a selective inhibitor of respiratory syncytial virus (RSV) replication. It demonstrates significant antiviral activity against RSV, making it a valuable tool for researchers studying RSV infections and related therapeutic interventions. This reagent can facilitate investigations into viral pathogenesis and the development of antiviral strategies. -
RSV Inhibitor
4,5-O-Dicaffeoyl quinic acid methyl ester is a potent antiviral agent specifically targeting respiratory syncytial virus (RSV). It exhibits strong inhibitory activity with an IC50 value of 0.63 μg/mL, indicating effective suppression of viral replication. The compound's safety profile is substantiated by a CC50 of 118.68 μg/mL, supporting its potential use in research applications focused on RSV-related therapeutic strategies. -
SARS-CoV-2 3CL Protease Inhibitor
Ensitrelvir is a selective, non-covalent, and non-peptidic inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 13 nM. This compound has demonstrated significant antiviral activity against SARS-CoV-2, making it a valuable tool for research into COVID-19 treatments. It is particularly applicable in studies focused on viral replication and therapeutic interventions targeting coronavirus proteases. -
SARS-CoV-2 Inhibitor
Simnotrelvir is a potent inhibitor of SARS-CoV-2 3CLpro, demonstrating an IC50 value of 0.022 µM. This compound exhibits significant antiviral activity against SARS-CoV-2, making it a valuable tool in research focusing on COVID-19 treatment and prevention strategies. Its efficacy in inhibiting viral replication positions it as a critical reagent for investigations into therapeutic options for coronavirus infections. -
SARS-CoV-2 3CL Protease Inhibitor
Ensitrelvir fumarate is a non-covalent, non-peptidic inhibitor targeting the SARS-CoV-2 3CL protease, exhibiting an IC50 of 13 nM. This compound plays a critical role in the inhibition of viral replication by blocking a key enzymatic function essential for SARS-CoV-2 maturation. It is primarily utilized in research applications related to COVID-19 therapeutic development and the exploration of antiviral strategies. -
SARS-CoV-2 Mpro Inhibitor
(±)-Alliin is a compound derived from garlic, recognized for its potential inhibitory effects on the main protease of SARS-CoV-2 (Mpro). This compound demonstrates antiviral activity, making it a candidate for research aimed at understanding and combating SARS-CoV-2 replication and infection mechanisms. Its application in biochemical studies can contribute to the development of therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
Leritrelvir is an orally active inhibitor of the SARS-CoV-2 main protease, displaying a slow-tight binding mechanism with a Ki value of 8.6 nM. This compound is valuable for research focused on therapeutic strategies against COVID-19, demonstrating potential in the development of antiviral agents aimed at mitigating SARS-CoV-2 replication. Its efficacy as a protease inhibitor makes it a significant candidate for studying protease-related pathways and antiviral drug design. -
SARS-CoV-2 3C-like protease (3CLpro) Inhibitor
Secutrelvir is a potent inhibitor of the SARS-CoV-2 3C-like protease (3CLpro), demonstrating IC50 values of 0.655 nM and 0.697 nM. By forming a reversible covalent bond with the catalytic cysteine C145, Secutrelvir effectively inhibits viral replication, making it a valuable tool in combating SARS-CoV-2. Its efficacy against various SARS-CoV-2 variants supports its potential applications in research focused on coronavirus disease 2019 (COVID-19). -
SARS-CoV-2 Inhibitor
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 24 nM against wild-type SARS-CoV-2 Mpro. By inhibiting viral polyprotein processing, it effectively disrupts viral replication. Pomotrelvir demonstrates broad antiviral activity against various SARS-CoV-2 variants, including Omicron, and shows an additive effect when co-administered with nucleoside analogs targeting viral RNA synthesis. It is primarily utilized in the research and development of antiviral therapeutics for COVID-19 caused by SARS-CoV-2 and its variants. -
SARS-CoV-2 Inhibitor
Iscartrelvir is a non-covalent inhibitor that targets the 3CLpro protein of SARS-CoV-2. This compound demonstrates potent inhibitory activity against multiple SARS-CoV-2 variants, including Alpha, Beta, Gamma, Delta, Lambda, and Omicron, as well as two other coronaviruses, SARS-CoV and MERS-CoV. Iscartrelvir is valuable for research applications focused on antiviral strategies and the study of coronavirus proteases. -
SARS-CoV-2 Membrane Protein Inhibitor
CIM-834 is an orally bioavailable inhibitor targeting the SARS-CoV-2 membrane protein. It effectively disrupts the assembly of infectious viral particles while preserving viral RNA synthesis. In preclinical studies, CIM-834 has demonstrated a capability to reduce viral titers in lung tissues of SCID mice and prevent the transmission of SARS-CoV-2 among Syrian hamsters. Additionally, it exhibits inhibitory effects on the replication of both SARS-CoV-2 variants and SARS-CoV, making it relevant for COVID-19 research applications. -
SARS-CoV-2 Inhibitor
MPI60 is a potent inhibitor of SARS-CoV-2 main protease (MPro), demonstrating significant antiviral activity and low cellular cytotoxicity. This compound exhibits high metabolic stability in vitro, making it a valuable tool for SARS-CoV-2 research and therapeutic development. Researchers can utilize MPI60 to explore the molecular mechanisms of viral replication and potential intervention strategies. -
SARS-CoV Inhibitor
GS-621763 is an orally bioavailable prodrug of GS-441524 that serves as a potent inhibitor of SARS-CoV-2. It demonstrates significant antiviral activity, effectively reducing viral load to undetectable levels in ferrets infected with SARS-CoV-2. This compound is valuable for research applications related to coronavirus pathogenesis and therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
Cichoriin is a potent inhibitor of SARS-CoV-2, targeting viral replication and entry into host cells. It demonstrates significant antiviral activity, making it a valuable candidate for research into therapies for severe COVID-19. This compound may facilitate studies on the pathogenesis of the virus and the development of effective treatment strategies. -
SARS-CoV-2 MPro Inhibitor
Mpro inhibitor N3 is a potent inhibitor of the SARS-CoV-2 main protease (MPro), demonstrating an EC50 value of 16.77 µM. This compound exhibits antiviral activity not only against SARS-CoV-2 but also against other coronaviruses, including HCoV-229E, FIPV, IBV, and MHV-A59. Its ability to inhibit viral replication makes it a valuable tool for research in antiviral drug development and coronavirus disease studies. -
SARS-CoV-2 Inhibitor
AT-9010 tetrasodium is a potent inhibitor of the nucleotidyltransferase (NiRAN) domain, crucial for the replication of SARS-CoV-2. This triphosphate active metabolite of AT-527 demonstrates significant antiviral activity by disrupting viral replication processes. Its application is primarily focused on research related to SARS-CoV-2 and the development of therapeutic interventions for COVID-19. -
SARS-CoV-2 PLpro Inhibitor
PF-07957472 is an orally active inhibitor of the SARS-CoV-2 papain-like protease (PLpro). It demonstrates significant antiviral activity, evidenced by an EC50 of 13.9 nM in SARS-CoV-2 infected normal human bronchial epithelial (NHBE) cells. Additionally, PF-07957472 exhibits protective effects in a mouse model adapted for COVID-19, making it a valuable reagent for studying antiviral mechanisms and therapeutic applications related to SARS-CoV-2 infection. -
SARS-CoV Replication Inhibitor
SSAA09E2 is an inhibitor of SARS-CoV replication, specifically targeting the early interactions between the SARS spike protein (S) and its receptor, Angiotensin Converting Enzyme-2 (ACE2). This compound exhibits significant antiviral activity, making it a valuable tool for research into therapeutic strategies against SARS-CoV infections. Its application in studying viral entry mechanisms and potential treatments provides critical insights into coronavirus-related diseases. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-13 is a potent inhibitor of SARS-CoV-2 with a reported IC50 of 0.057 μM. As a niclosamide analogue, it demonstrates enhanced stability in human plasma and liver S9 enzyme assays compared to its predecessor, which may lead to improved bioavailability and longer half-life upon oral administration. This compound is valuable for research applications focused on antiviral therapies and understanding SARS-CoV-2 inhibition mechanisms. -
SARS-CoV-2 3CL Proteas Inhibitor
SARS-CoV-2 3CLpro-IN-13 is a highly effective inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 21 nM. This compound demonstrates significant anti-coronavirus activity, making it a valuable tool for research focused on SARS-CoV-2 inhibition and antiviral drug development. It is suitable for studies investigating the biochemical mechanisms underlying coronavirus replication and the potential therapeutic strategies against SARS-CoV-2. -
HIV Inhibitor Prodrug
HIV-IN-13 prodrug is designed as a prodrug of an HIV inhibitor, engaging specifically with viral components upon conversion. In the presence of glutathione (GSH), this compound exhibits significant antiviral activity, demonstrating EC50 values of 10 μM and 8.2 μM against HIV-1 at concentrations of 1 mM and 2 mM GSH, respectively. This prodrug serves as a valuable tool for research focused on HIV infection and therapeutic development. -
HIV-1 Inhibitor
NB-64 is an orally active inhibitor of HIV-1 that targets viral replication. Its significant antiviral activity makes it a valuable tool for research into HIV infections and the development of therapeutic strategies. This compound contributes to a better understanding of HIV pathogenesis and potential treatment options. -
HIV Inhibitor
PNU-142721 is a reverse transcriptase inhibitor that targets HIV by effectively inhibiting various type I variants. This compound serves as a valuable tool in HIV research, particularly in the study of viral replication and resistance mechanisms. Its dual function as a PXR agonist further enhances its relevance in investigating drug metabolism and therapeutic strategies against HIV. -
HIV Integrase Inhibitor
Lepetegravir is a potent HIV integrase inhibitor that exerts its antiviral effects by blocking the integration of viral DNA into the host genome. With an EC50 value of 0.98 nM in MT-4 cells, it demonstrates strong efficacy in suppressing HIV replication. Lepetegravir is applicable in research aimed at understanding HIV pathogenesis and developing antiretroviral therapies. -
HIV-1 Integrase Inhibitor
Integracin B is a potent inhibitor targeting HIV-1 integrase through a dimeric alkyl aromatic structure. It effectively inhibits both the coupled and strand transfer activities of the integrase, making it a valuable tool for studying HIV-1 replication and integration processes. This compound is suitable for research applications focused on antiviral drug development and the mechanistic understanding of integrase-mediated viral entry. -
HIV Inhibitor
HIV-1 Inhibitor-9 is a potent inhibitor targeting HIV-1, effectively inhibiting both wild-type and various non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant strains at low nanomolar concentrations. This compound demonstrates significant antiviral activity, making it a valuable tool for research into HIV treatment and drug resistance mechanisms. Its efficacy against resistant strains supports its potential use in therapeutic studies and drug development efforts aimed at combating HIV-1 infection. -
Reverse Transcriptase Inhibitor
Inophyllum B is a potent inhibitor of HIV reverse transcriptase, exhibiting an impressive IC50 value of 38 nM. This compound effectively inhibits HIV-1 in vitro cell cultures with an IC50 of 1.4 μM. Inophyllum B is isolated from the acetone extract of the giant African snail, Achatina fulica, making it a valuable reagent for research applications focused on antiviral drug development and the mechanisms of HIV replication. -
HIV Inhibitor
Tripterifordin is a potent inhibitor of HIV replication, specifically targeting H9 lymphocyte cells. It demonstrates significant anti-HIV activity with an EC50 value of 3100 nM. This compound is valuable for research applications aimed at understanding HIV pathogenesis and developing therapeutic strategies against HIV infection. -
HIV Inhibitor
UK-88947 hydrochloride is a potent HIV protease inhibitor, primarily targeting HIV-1 replication. It effectively disrupts the early stages of the viral life cycle when administered to cells prior to infection. Additionally, UK-88947 hydrochloride inhibits viral protease activity during infection, thereby significantly impacting viral replication. This compound is valuable for research focused on developing therapeutic strategies against HIV. -
HIV Inhibitor
(D-Ala)-Peptide T is an octapeptide that acts as an HIV inhibitor by targeting the HIV-1 envelope glycoprotein gp120. This compound has been shown to release chemokines and protect against neuronal death induced by gp120. It is a valuable reagent for research into infectious diseases and neurological disorders, particularly AIDS-related dementia. -
HIV-1 Inhibitor
HIV-1 Inhibitor-29 is a potent inhibitor targeting the HIV-1 virus, demonstrating an EC50 of 2.18 μM against the HIV-1 IIIB strain. This compound exhibits significant anti-resistance properties against the F227L/V106A mutant strain, with an EC50 of 0.974 μM, while maintaining low cytotoxicity in MT-4 cells (CC50 = 211 μM). HIV-1 Inhibitor-29 is a valuable tool for research focused on AIDS and HIV-1 therapeutic development. -
Non-Nucleoside rReverse Transcriptase Inhibitor
UC-84 (NSC-615985) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent anti-HIV activity. By targeting the reverse transcriptase enzyme, UC-84 effectively disrupts viral replication, making it a valuable compound for HIV research. Its application extends to studies focused on the mechanisms of viral resistance and the development of novel therapeutic strategies against HIV. -
HIV-1 Inhibitor
NNRT-IN-1 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor targeting HIV-1. This compound demonstrates significant anti-resistance efficacy, effectively inhibiting wild-type HIV-1 as well as five mutant strains, with EC50 values in the nanomolar range. Additionally, NNRT-IN-1 exhibits favorable pharmacokinetic properties, making it a valuable tool for research applications in HIV therapeutics. -
HIV Inhibitor
(+)-Carbovir is a nucleoside analog specifically designed to inhibit human immunodeficiency virus type 1 (HIV-1). Its enhanced chemical and metabolic stability contributes to its antiviral efficacy. This compound serves as a valuable tool in AIDS research, facilitating studies aimed at understanding and combating HIV infection. -
HIV-1 RT Inhibitor
Tivirapine is a non-nucleoside inhibitor targeting HIV-1 reverse transcriptase (RT), demonstrating potent antiviral activity with an EC50 value of 4 nM. This compound effectively inhibits the Y181C mutant of HIV-1 RT, offering a valuable tool for studying drug resistance mechanisms and evaluating therapeutic strategies against HIV-1 infection. Its application is relevant in both basic research and development of novel antiviral therapies. -
HIV-1 Inhibitor
HIV-1 inhibitor-64 (Compound 7c) is a potent antagonist targeting HIV-1, demonstrating effective inhibition of both wild-type and resistant mutants, specifically E138K/Q148K and G140S/Q148R, with EC50 values of 62.5 nM and 11.3 nM, respectively. This compound exhibits significant antiviral activity, making it a valuable tool for AIDS research and studies focused on HIV-1 resistance mechanisms. -
HIV-1 Inhibitor
HIV-1 inhibitor-40 (Compound 4ab) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1 with an EC50 of 1.9 nM, demonstrating potent antiviral activity. This compound exhibits minimal interaction with cytochrome P450 enzymes, with IC50 values of 5.16 μM for CYP2C9 and 4.51 μM for CYP2C19, indicating its favorable profile for therapeutic applications. Notably, HIV-1 inhibitor-40 shows no significant acute toxicity in vivo, making it a promising candidate for further research in HIV treatment. -
HIV Inhibitor
Influenza antiviral conjugate-1 (INT-2) is an HIV inhibitor that exhibits potent cell fusion inhibition. This compound serves as a click chemistry reagent, featuring an alkyne group capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its application in biological research allows for the development of innovative therapeutic strategies and the study of viral entry mechanisms. -
HIV REV/RRE Interaction Inhibitor
Niruriside is an inhibitor of the HIV REV/RRE complex, specifically targeting the interaction between the HIV REV protein and RRE RNA with an IC50 of 3.3 μM. This compound exhibits selectivity, showing no significant effects on the unrelated R17 capsid protein/operator RNA binding system. While Niruriside does not protect CEM-SS cells from acute HIV-1 infection, it serves as a valuable tool for investigating the mechanisms of HIV infection and the role of the REV/RRE interaction in viral replication and pathogenesis. -
HIV-1 Inhibitor
L 696229 is a selective inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), demonstrating significant antiviral activity. This compound is primarily utilized in the study of HIV replication and the development of antiretroviral therapies, offering insights into viral resistance mechanisms and potential therapeutic interventions. Its specificity for RT makes it a valuable tool in HIV research and drug discovery. -
HIV-1 Inhibitor
Fosamprenavir sodium is an orally active inhibitor targeting HIV-1 protease and functions as a prodrug for Amprenavir. Upon administration, it is hydrolyzed by cell phosphatases in the intestinal epithelium to release Amprenavir, which inhibits HIV-1 protease by binding to its active site. This binding prevents the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the maturation of infectious virus particles. Fosamprenavir sodium is valuable for research on human immunodeficiency virus (HIV-1) infection. -
Non-Nucleoside rReverse Transcriptase Inhibitor
UC-38 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent anti-HIV activity. This compound disrupts the reverse transcription process essential for the viral replication cycle, making it a valuable tool for research on HIV mechanisms and potential therapeutics. Its application extends to the investigation of NNRTIs in the development of effective HIV treatment strategies. -
HIV-1 Inhibitor
HIV-1 inhibitor-35 is a potent inhibitor of HIV-1, exhibiting EC50 values of 80 nM and 70 nM against LTR and CMV in HEK293 cells, respectively. This compound also demonstrates cytotoxic activity against HepG2 liver cancer cells, with a CC50 of 40 nM. HIV-1 inhibitor-35 is suitable for research applications in HIV-1 latency reversal and antiviral therapeutic investigations. -
HIV Inhibitor
GB-1a is a biflavanone that functions as an inhibitor of HIV-1 reverse transcriptase, demonstrating an IC50 value of 236 μM and an EC50 of 38.0 μM for HIV-1 replication. This compound effectively prevents the conversion of HIV-1 genomic RNA into DNA, making it a valuable tool for research on AIDS and HIV-1 infection. Additionally, GB-1a can be naturally sourced from the heartwood of Garcinia multiflora Champ, further emphasizing its potential for biological study. -
HIV-1 Inhibitor
AIC-292 is a selective inhibitor of HIV-1 nonnucleoside reverse transcriptase, demonstrating potent antiviral activity against wild-type HIV-1 laboratory strains at low nanomolar concentrations. This compound exhibits significant in vivo efficacy in mouse xenograft models, making it a valuable tool for research into HIV-1 infection and antiretroviral therapies. AIC-292 may aid in the development of innovative therapeutic strategies targeting HIV-1. -
HIV Inhibitor
HIV-1 inhibitor-38 is a potent HIV-1 inhibitor that exhibits effective antiviral activity against the virus responsible for HIV/AIDS. Its unique mechanism of action positions it as a potential candidate for further development as a latency-reversing agent, making it a valuable tool in HIV research and therapeutic investigation. This compound is particularly relevant for studies focused on viral eradication and understanding HIV latency. -
Non-Nucleoside reverse Transcriptase Inhibitor
Bavtavirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) that targets the reverse transcriptase enzyme essential for HIV replication. It is utilized in highly active antiretroviral therapy (HAART) regimens and has significant implications in HIV disease research. Bavtavirine's mechanism of action makes it a valuable tool in studying HIV pathogenesis and developing therapeutic strategies against the virus.
